Skip to main content

Cisapride Pregnancy and Breastfeeding Warnings

Brand names: Propulsid

Cisapride Pregnancy Warnings

Cisapride has been assigned to pregnancy category C by the FDA. Animal studies have failed to reveal evidence of teratogenicity, although embryo- and fetotoxicity are seen in rats and rabbits at high doses (150 mg/kg/day and 20 mg/kg/day, respectively). There are no controlled data in human pregnancy. Cisapride should only be given during pregnancy when benefit outweighs risk.

See references

Cisapride Breastfeeding Warnings

Cisapride is excreted into human milk in small amounts. The manufacturer recommends cautious use during lactation. However, cisapride is considered compatible with breast-feeding by the American Academy of Pediatrics.

In a study of ten puerperal women administered cisapride 20 mg by mouth three times a day for 4 days, cisapride milk concentrations averaged 6.2 ng/mL, with corresponding serum concentrations averaging 137 ng/mL one hour after the last dose.

See references

See also

References for pregnancy information

  1. (2001) "Product Information. Propulsid (cisapride)." Janssen Pharmaceuticals

References for breastfeeding information

  1. Hofmeyr GJ, Sonnendecker EW (1986) "Secretion of the gastrokinetic agent cisapride in human milk." Eur J Clin Pharmacol, 30, p. 735-6
  2. (2001) "Product Information. Propulsid (cisapride)." Janssen Pharmaceuticals
  3. Committee on Drugs, 1992 to 1993 (1994) "The transfer of drugs and other chemicals into human milk." Pediatrics, 93, p. 137-50

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer